As active pharmaceutical ingredients (APIs) continue to grow more complex, process chemists must reconcile more elaborate synthetic pathways with a continued push to reach the clinic rapidly. To achieve efficient API manufacturing, drug sponsors are looking for fast and effective strategies to fulfill raw material needs and avoid supply chain hiccups.
In the webinar, "Meeting the Challenge of Rising API Complexity," experts from Lonza Small Molecules and Elsevier Life Sciences discussed the impact of leveraging predictive retrosynthesis route design and a custom building block library to yield time and cost savings for sponsors developing complex APIs. In the post-webinar Q&A, they tackled questions on the impact of artificial intelligence (AI) on route design, cost-effective modifications, and overall timelines for route scouting.
Read the Q&A for more.